btk and bcl2 inhibitor resistance in cll: session highlights
Published 2 years ago • 126 plays • Length 3:12Download video MP4
Download video MP3
Similar videos
-
1:27
advances in btk and bcl2 inhibitors for cll
-
2:12
understanding and overcoming resistance to btk and bcl-2 inhibitors in cll
-
4:05
bcl2 and btk dual-inhibition with sonrotoclax zanubrutinib in previously untreated cll and sll
-
5:00
comparing btk and bcl-2 inhibitor outcomes in different cll subgroups
-
11:55
updates in cll from eha 2024: combinations of btk and bcl2 inhibitors, btk degraders, and more
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
1:26
combining btk and bcl-2 inhibitors for the treatment of cll
-
2:25
btk and bcl-2 inhibitor combination therapies in cll
-
1:46
managing the side effects associated with btki treatment for cll
-
3:52
maintenance therapy with revumenib following allosct in kmt2ar and npm1-mutated acute leukemias
-
5:06
evolution of btk inhibitors in cll
-
2:25
outcomes & healthcare utilization cost of patients with cll refractory to btk and bcl-2 inhibitors
-
1:24
sequencing of btk inhibitors in cll
-
1:45
the importance of real-world data in cll & efficacy of btk and bcl-2 inhibitors in the real world
-
1:19
outcomes of cll patients following treatment with a covalent btk and bcl2 inhibitor
-
1:59
choosing the best btk inhibitor for managing cll
-
2:37
resistance to acalabrutinib in cll is mediated by btk mutations
-
2:11
pre-clinical study on the dual bcl2/bcl-xl inhibitor azd0466 for the treatment of cll
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
1:05
btk degraders in the treatment of cll
-
1:13
dual-targeted regimens for the treatment of cll: anti-cd20 antibodies, btki, and bcl2i
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients